ResMed Inc. (NYSE:RMD) is set to post its quarterly earnings results after the market closes on Tuesday, August 1st. Analysts expect ResMed to post earnings of $0.75 per share for the quarter.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, April 27th. The medical equipment provider reported $0.71 EPS for the quarter, topping the consensus estimate of $0.70 by $0.01. The company had revenue of $514.20 million during the quarter, compared to the consensus estimate of $525.84 million. ResMed had a net margin of 15.96% and a return on equity of 22.53%. The company’s quarterly revenue was up 13.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.68 EPS. On average, analysts expect ResMed to post $2.8 EPS for the current fiscal year and $3.12 EPS for the next fiscal year.

Shares of ResMed Inc. (NYSE RMD) traded down 0.32% during mid-day trading on Thursday, hitting $77.41. 434,095 shares of the stock traded hands. The stock has a market cap of $10.98 billion, a price-to-earnings ratio of 33.95 and a beta of 0.84. ResMed Inc. has a 52 week low of $56.59 and a 52 week high of $79.44. The firm’s 50-day moving average is $76.83 and its 200-day moving average is $71.43.

A number of equities analysts recently commented on RMD shares. J P Morgan Chase & Co downgraded ResMed from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $72.00 to $71.00 in a report on Thursday, April 20th. Zacks Investment Research raised ResMed from a “sell” rating to a “hold” rating in a research note on Wednesday, April 12th. William Blair reaffirmed an “outperform” rating on shares of ResMed in a research note on Thursday, April 13th. BMO Capital Markets reaffirmed a “hold” rating on shares of ResMed in a research note on Friday, May 12th. Finally, Citigroup Inc. cut ResMed from a “buy” rating to a “neutral” rating in a research note on Friday, April 28th. Four investment analysts have rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $64.50.

COPYRIGHT VIOLATION WARNING: “ResMed Inc. (NYSE:RMD) Scheduled to Post Earnings on Tuesday” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/07/27/resmed-inc-nysermd-scheduled-to-post-earnings-on-tuesday.html.

In other news, Director Peter C. Farrell sold 20,000 shares of the stock in a transaction on Thursday, May 4th. The stock was sold at an average price of $68.75, for a total value of $1,375,000.00. Following the sale, the director now directly owns 321,557 shares of the company’s stock, valued at $22,107,043.75. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Brett Sandercock sold 1,250 shares of the stock in a transaction on Monday, May 1st. The stock was sold at an average price of $68.60, for a total value of $85,750.00. Following the completion of the sale, the chief financial officer now directly owns 62,783 shares in the company, valued at $4,306,913.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 180,261 shares of company stock worth $13,560,373. 1.97% of the stock is owned by insiders.

ResMed Company Profile

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Earnings History for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.